Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism.
Serotonin (5-HT) has been proposed to exert an inhibitory effect on central dopamine activity, so increased brain 5-HT would be expected to reduce tardive dyskinesia (TD). Therefore a new antidepressant, a selective 5-HT uptake inhibitor, citalopram, was evaluated in 13 psychiatric patients with TD, 11 of whom also had neuroleptic-induced parkinsonism. Drug effects during active treatment (20-40 mg/day for 3 weeks) and pre- and posttreatment placebo periods were scored blindly from videotapes recorded weekly. TD, parkinsonism, and eyeblinking rates were unchanged. Psychiatric symptoms showed no significant changes, and no side effects were reported. The data suggest that increasing 5-HT activity by 5-HT uptake inhibitors has no significant beneficial effect in TD, but citalopram may be advantageous in the treatment of depressed patients who also have TD, as this drug does not aggravate TD as do tricyclic antidepressants.
Korsgaard
S
S
Noring
U
U
Povlsen
U J
UJ
Gerlach
J
J
D000328:Adult; D000368:Aged; D015283:Citalopram; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011437:Propylamines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D011437:Propylamines; D012702:Serotonin Antagonists; D015283:Citalopram